Puzzling through fragment-based drug design

被引：32

作者：

Hajduk, Philip J. ^{[1
]}

机构：

[1] Abbott Labs, Dept Adv Technol, Abbott Pk, IL 60064 USA

来源：

NATURE CHEMICAL BIOLOGY | 2006年 / 2卷 / 12期

关键词：

D O I：

10.1038/nchembio1206-658

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Fragment-based drug design capitalizes on the modular binding of low-molecular-weight, low-affinity ligands. However, the deconstruction of lead-like inhibitors into putative fragments reveals the surprising complexity of dealing with low-affinity leads, thereby challenging oversimplification of these leads and highlighting the richness of their chemical diversity and molecular recognition.

引用

页码：658 / 659

页数：2

共 5 条

[1] Deconstructing fragment-based inhibitor discovery [J].

Babaoglu, Kerim ;

Shoichet, Brian K. .

NATURE CHEMICAL BIOLOGY, 2006, 2 (12) :720-723

[2] Fragment-based drug discovery [J].

Erlanson, DA ;

McDowell, RS ;

O'Brien, T .

JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (14) :3463-3482

[3] Druggability indices for protein targets derived from NMR-based screening data [J].

Hajduk, PJ ;

Huth, JR ;

Fesik, SW .

JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (07) :2518-2525

[4]

HAJDUK PJ, 2006, METHODS PRINCIPLES M, V34, P181

[5] Molecular complexity and its impact on the probability of finding leads for drug discovery [J].

Hann, MM ;

Leach, AR ;

Harper, G .

JOURNAL OF CHEMICAL INFORMATION AND COMPUTER SCIENCES, 2001, 41 (03) :856-864

← 1 →